VolitionRx Limited (NYSE:VNRX - Get Free Report) CEO Cameron John Reynolds acquired 181,818 shares of the firm's stock in a transaction on Wednesday, March 26th. The shares were bought at an average price of $0.55 per share, for a total transaction of $99,999.90. Following the completion of the transaction, the chief executive officer now owns 2,299,222 shares of the company's stock, valued at approximately $1,264,572.10. This trade represents a 8.59 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
VolitionRx Price Performance
Shares of VNRX stock opened at $0.53 on Friday. The company's 50-day simple moving average is $0.59 and its two-hundred day simple moving average is $0.64. The company has a market capitalization of $48.93 million, a P/E ratio of -1.47 and a beta of 1.09. VolitionRx Limited has a one year low of $0.43 and a one year high of $1.02.
Institutional Trading of VolitionRx
Hedge funds have recently added to or reduced their stakes in the business. Two Sigma Securities LLC bought a new stake in shares of VolitionRx in the 4th quarter valued at about $29,000. Millennium Management LLC purchased a new stake in VolitionRx during the fourth quarter worth $36,000. Northern Trust Corp boosted its position in VolitionRx by 32.0% during the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company's stock valued at $71,000 after acquiring an additional 28,579 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of VolitionRx by 15.1% during the 3rd quarter. Geode Capital Management LLC now owns 730,448 shares of the company's stock worth $439,000 after purchasing an additional 95,900 shares during the last quarter. Finally, Lagoda Investment Management L.P. boosted its position in VolitionRx by 24.3% during the fourth quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company's stock valued at $4,546,000 after purchasing an additional 1,481,000 shares in the last quarter. 8.09% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
A number of analysts recently issued reports on VNRX shares. D. Boral Capital restated a "buy" rating and issued a $5.00 price target on shares of VolitionRx in a research report on Thursday, March 20th. StockNews.com started coverage on shares of VolitionRx in a research note on Friday. They set a "sell" rating for the company.
Check Out Our Latest Stock Analysis on VolitionRx
About VolitionRx
(
Get Free Report)
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
